DeKang Medical's Q2 results beat expectations, raises lower end of full-year revenue guidance

Glonghui, July 31 | Continuous glucose monitor manufacturer DexCom announced its second quarter results, with revenue rising approximately 13% year-on-year to $1.31 billion, surpassing the market expectation of $1.29 billion. Adjusted earnings per share were $0.70, also exceeding the market expectation of $0.61. The company raised the lower end of its full-year revenue guidance, now projecting revenue between $5.18 billion and $5.25 billion, compared to its previous estimate of $5.16 billion to $5.25 billion, and the market expectation of $5.22 billion.